Document Detail

Clinical and geographical variation in prophylactic and therapeutic treatments for pre-eclampsia in the UK.
MedLine Citation:
PMID:  20175876     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate the clinical and geographical variation in the use of aspirin in women at high risk of pre-eclampsia, and in the use of antihypertensive drugs and magnesium sulphate in women with established pre-eclampsia. DESIGN: Analysis of vitamins in pre-eclampsia (VIP) trial database. SAMPLE: A total of 2399 women at increased risk of pre-eclampsia in 25 UK hospitals. METHODS: An analysis of a large prospectively validated database of high-risk women in the UK was undertaken to assess aspirin use across different risk groups and to evaluate the use of antihypertensives and magnesium sulphate in 370 women who developed pre-eclampsia. Logistic regression was employed to compare drug use between region and by recognised clinical indicators. MAIN OUTCOME MEASURES: Usage of aspirin, antihypertensive drugs and magnesium sulphate. RESULTS: Of the women with known risk factors at trial entry, 24% (569/2399) received low-dose aspirin. Aspirin usage varied widely between risk groups [from 5% (19/378) in women with multiple pregnancy to 94% (50/53) in women with antiphospholipid syndrome] and between geographical regions [from 8% (20/248) to 49% (95/193)]. Three hundred and seventy women developed pre-eclampsia, 52% (n = 193) of whom received new or additional antihypertensives after 20 weeks of gestation; 34% (77/224) with a maximum recorded systolic blood pressure of >OR=160 mmHg in the second half of pregnancy did not receive antihypertensive treatment; 17% (62/370) of women with pre-eclampsia received magnesium sulphate prophylactically. CONCLUSIONS: Prophylactic and treatment regimes for pre-eclampsia in the UK vary by region and risk group.
L C Chappell; P Seed; S Enye; A L Briley; L Poston; A H Shennan
Related Documents :
11483926 - Inhibition of cyclooxygenase but not nitric oxide synthase influences effects on the hu...
14672476 - Human chorionic gonadotropin and vascular endothelial growth factor in normal and compl...
2234646 - Poor participation of nulliparous women in a low dose aspirin study to prevent preeclam...
12623936 - Family history of hypertension and type 2 diabetes in relation to preeclampsia risk.
20005516 - Lipoprotein-associated phospholipase a(2), inflammatory biomarkers, and risk of cardiov...
23996556 - Brief communication: body mass index, body adiposity index, and percent body fat in asi...
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2010-02-22
Journal Detail:
Title:  BJOG : an international journal of obstetrics and gynaecology     Volume:  117     ISSN:  1471-0528     ISO Abbreviation:  BJOG     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-08     Completed Date:  2010-06-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100935741     Medline TA:  BJOG     Country:  England    
Other Details:
Languages:  eng     Pagination:  695-700     Citation Subset:  AIM; IM    
Maternal and Fetal Research Unit, Division of Reproduction and Endocrinology, King's College London School of Biomedical and Health Sciences, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticonvulsants / therapeutic use*
Antihypertensive Agents / therapeutic use*
Aspirin / therapeutic use*
Great Britain
Magnesium Sulfate / therapeutic use*
Platelet Aggregation Inhibitors / therapeutic use*
Pre-Eclampsia / drug therapy*,  prevention & control
Residence Characteristics
Risk Factors
Reg. No./Substance:
0/Anticonvulsants; 0/Antihypertensive Agents; 0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin; 7487-88-9/Magnesium Sulfate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Few fathers-to-be prefer caesarean section for the birth of their baby.
Next Document:  FoxP1 promotes midbrain identity in embryonic stem cell-derived dopamine neurons by regulating Pitx3...